-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4382 Highly Heterogeneous Cellular Composition and Neighborhood Architecture within the Follicular Lymphoma Tumor Microenvironment

Program: Oral and Poster Abstracts
Session: 622. Lymphomas: Translational – Non-Genetic: Poster III
Hematology Disease Topics & Pathways:
Research, Translational Research, Lymphomas, Non-Hodgkin lymphoma, B Cell lymphoma, Bioinformatics, Diseases, Immunology, Lymphoid Malignancies, Computational biology, Biological Processes, Emerging technologies, Technology and Procedures, Study Population, Human, Imaging, Omics technologies
Monday, December 9, 2024, 6:00 PM-8:00 PM

Paul R Buckley1*, Julie Chan, PhD2*, Cynthia Bishop, PhD3*, Timothy Woo, MD4*, Katrina Todd5*, Elizabeth Phillips, MD6, Alessia Bottos, PhD7*, Christopher R. Bolen, PhD8*, Verena Passerini, PhD9*, Oliver Weigert, MD10,11 and Piers E.M. Patten, MBChB, FRCP, FRCPath, PhD12,13*

1Comprehensive Cancer Centre, King's College London / GSTT, London, United Kingdom
2King's College London, London, United Kingdom
3Guy's Hospital, Guy's & St Thomas NHS Foundation Trust, London, United Kingdom
4King's College London / KCH, London, United Kingdom
5Guy's & St Thomas NHS Foundation Trust, London, United Kingdom
6The Christie NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom
7F. Hoffmann-La Roche Ltd, Basel, Switzerland
8Genentech, Inc., South San Francisco, CA
9Department of Medicine III, Hospital of the Ludwig-Maximilians-University (LMU), Munich, Germany
10Department of Internal Medicine III, University of Munich, Munich, Germany
11Experimental Leukemia and Lymphoma Research (ELLF), University Hospital, LMU Munich, Munich, Germany
12Comprehensive Cancer Centre, King's College London, London, United Kingdom
13King's College Hospital, London, United Kingdom

The variable clinical course and response to treatment of Follicular Lymphoma (FL) is strongly influenced by its tumor microenvironment (TME). Indeed, cellular interactions dictate pro- and anti-tumor processes within the TME, although these mechanisms remain incompletely understood. Multiple bulk and single-cell studies have shed light on the TME with prognostic implications. For example, a macrophage gene signature as well as a ‘T cell depleted’ milieu have been associated with inferior clinical outcomes.

Imaging Mass Cytometry (IMC) permits the multiplexed assessment of over 40 markers concomitantly, superseding the limits of conventional immunohistochemistry, thus enabling detailed single cell spatial profiling of the TME. For comprehensive analysis of tumor immune architecture within FL, we first optimized a 31-plex panel to capture tumor, immune and stromal cell subsets, as well as functional information such as memory and effector status, proliferation, activation and exhaustion. Fixed formalin paraffin embedded (FFPE) biopsies from untreated FL patients enrolled on the GALLIUM trial (NCT01332968), assessing frontline chemo-immunotherapy regimens, were subjected to IMC and 381 high-dimensional images were acquired.

After quality control, we analysed >3.5 million cells across 340 high-dimensional images. Cell phenotyping identified ~78 cell populations including lymphoma cells, CD4+ and CD8+ T cell subsets (including T follicular helper (Tfh), memory, naïve, exhausted) and a range of non-lymphoid cells e.g. myeloid and stromal cells. As expected, CD20+ B cells were expanded in FL images compared with control lymphoid samples (~56% vs. ~15% respectively p<0.05). Consistent with previous literature, we found an expansion of CD4+ T cells in FL (~20%) compared with control tissue (~12% p<0.05). We have additionally identified sets of samples enriched for CD57+ T cells. The presence of these cells has previously been associated with inferior survival in FL. Furthermore, we have observed that parent lineage abundance (e.g. CD20+ cells, CD3+ cells) identified via our phenotyping of FFPE biopsies were consistent with CIBERSORTx deconvolution analysis from patient-matched RNA-seq samples, improving confidence in our phenotypic labels.

We next analysed cellular neighborhoods, defining ten distinct FL environments. Analysis was performed i) at the level of neighborhoodcellular composition, and ii) at the level of relative proportions of identified neighborhoods within images. In terms of neighborhood cellular composition, among visually similar tissue components, we found striking variability. For example, we assessed the cellular composition of the neighborhoods making up follicles (as defined by the presence of CD21+ meshworks). In some cases, these neighborhoods were very homogenous with the cellular infiltrate consisting almost exclusively of lymphoma CD20+ cells. In other cases, we found that such neighborhoods were highly heterogenous encompassing diverse immune cell composition.

By analysing the relative abundance of different neighborhoods, we found sets of variable architectures across images. For example, the ‘lymphoma exclusive’ neighborhood dominated many images. We found that images with high abundance of this neighborhood typically also contained a scattered ‘lymphoma+, CD4/8T+, CD16+’ neighbourhood additionally exhibiting immunosuppressive Tregs cells, as well as CD57+ T cells. In contrast, a separate notable pattern of neighbourhood abundances was observed in a set of images containing organised follicular structures with detectable CD21+ meshwork, admixed with CD57+/- Tfh-like cells and macrophages. Here, this follicular structure was outlined by a thin layer of CD4+ T cells, CD57+PD1+ T cells and lymphoma cells. These images are completed by an interfollicular region containing neighborhoods comprising mixed immune subsets.

Ongoing work seeks to examine associations between such variable spatial arrangements with this clinically annotated dataset. This will provide a detailed characterization of how the spatial context and crosstalk of individual cells amid neighbourhoods within the FL TME specifically influences disease behavior, response to treatment and clinical outcome, which will likely extend and compliment those findings already described at bulk and single cell level.

Disclosures: Phillips: MSD: Research Funding. Bottos: F. Hoffmann-La Roche Ltd: Current Employment, Current equity holder in private company, Current holder of stock options in a privately-held company, Ended employment in the past 24 months. Bolen: Genetech: Current Employment. Patten: AstraZeneca: Honoraria, Research Funding; AbbVie: Honoraria, Other: Travel, accommodations, expenses, Research Funding; BeiGene: Honoraria, Other: Travel, accommodations, expenses, Research Funding; Janssen: Honoraria, Other: Travel, accommodations, expenses, Research Funding; Novartis: Research Funding.

*signifies non-member of ASH